This January, outcomes of psychedelic use were closely examined. Studies looked at how experiences are integrated, how challenging experiences lead to growth, and the relationship between psychedelic use and nature-relatedness.
In December we saw medium dose of psilocybin for depression, paradoxical wakefulness on 5-MeO-DMT, and many ketamine studies.
This is all the other psychedelic research that came out in January 2023. These papers don’t (yet) have their own page in our database.
What are the costs of psychedelic therapy? Who will pay for them and will it even be worth it for people, insurers, and companies?
This is all the other psychedelic research that came out in December 2022. These papers don’t (yet) have their own page in our database.
In November, we got results of COMPASS Pathways Phase II trial, antidepressants were found to weaken the effects of psilocybin while ketanserin has the potential to stop an LSD trip.
How can psychedelics become medicines through the effective altruism lens. A transcript of a fireside chat at EAGx Rotterdam.
This is all the other psychedelic research that came out in November 2022. These papers don’t (yet) have their own page in our database.
In October, natural language processing (NLP) was used to successfully predict clinical outcomes using data from a trial exploring psilocybin on treatment-resistant depression (TRD). The first real-world study assessing esketamine for TRD yielded positive results, while new evidence suggests people who microdose may build a tolerance which needs to be taken in future trials.
How psychedelics can be effective solutions to the worlds biggest problems. The effective altruism framework applied to psychedelics.